Home » Stocks » WINT

Windtree Therapeutics, Inc. (WINT)

Stock Price: $4.96 USD -0.08 (-1.49%)
Updated Mar 2, 2021 3:35 PM EST - Market open
Market Cap 84.78M
Revenue (ttm) n/a
Net Income (ttm) -32.49M
Shares Out 16.58M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $4.96
Previous Close $5.03
Change ($) -0.08
Change (%) -1.49%
Day's Open 5.69
Day's Range 4.91 - 5.69
Day's Volume 170,164
52-Week Range 4.80 - 10.06

News

Hide News
PRNewsWire - 3 months ago

WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions f...

GlobeNewsWire - 6 months ago

WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and me...

Benzinga - 8 months ago

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher on Wednesday. The company announced the initial European trial sites activated for its AEROSURF Bridging study and a collabor...

About WINT

Windtree Therapeutics, a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infant... [Read more...]

Industry
Biotechnology
IPO Date
Aug 8, 1995
CEO
Craig E. Fraser
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
WINT
Full Company Profile

Financial Performance

In 2019, WINT's revenue was $198,000, a decrease of -88.93% compared to the previous year's $1.79 million. Losses were -$27.48 million, 33.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for WINT stock is "Strong Buy" and the 12-month stock price forecast is 12.13.

Price Target
$12.13
Analyst Consensus: Strong Buy